Personalized neuroscience is an emerging interdisciplinary field that intersects neuroscience and personalized medicine, aiming to decipher individual variations in brain structure, function, and connectivity to customize interventions and treatments for diverse neurological and psychiatric conditions. Unlike conventional neuroscience approaches that often generalize findings across populations, personalized neuroscience recognizes the inherent diversity in brain function and treatment responses among individuals. Leveraging cutting-edge technologies such as functional magnetic resonance imaging (fMRI), electroencephalography (EEG), and genetics, researchers can delve deeper into the unique characteristics of each person's brain. A pivotal aspect of personalized neuroscience involves the use of biomarkers—genetic markers, neural activity patterns, and neuroimaging signatures—to characterize brain health and forecast responses to interventions. By pinpointing these biomarkers, clinicians can devise personalized treatment strategies tailored to an individual's distinct neurobiological profile. This approach holds promise across various domains, including mental health, neurodegenerative diseases, and cognitive enhancement. In psychiatry, personalized neuroscience enables optimization of medication selection and dosages based on a patient's neurobiological makeup, potentially minimizing side effects and enhancing treatment outcomes. Likewise, in neurodegenerative disorders like Alzheimer's and Parkinson's, it facilitates early detection and intervention, potentially delaying disease progression. Overall, personalized neuroscience represents a paradigm shift in understanding and addressing neurological and psychiatric conditions, paving the way for more effective, targeted interventions that improve patient outcomes and quality of life.
Title : Atypical presentation of Juvenile myoclonic epilepsy in a 16-year-old female: A case report
George Diaz, Memorial Healthcare Systems, United States
Title : Triple-network dysfunction, ME/CFS, and the NeuroPhysics Treatment Process “A dynamical systems perspective on psychophysical organization and environmental interaction”
Ken Ware, NeuroPhysics Therapy Institute and Research Centre, Australia
Title : Beyond plaques: 10-nanometer-scale pathoconnectomics of Alzheimer’s disease
Ons M Saad, Panluminate Inc., United States
Title : Results from the global phase 3 trial (IB1001-303) evaluating levacetylleucine in children and adults with ataxia-telangiectasia
Chidinma Ejim, IntraBio, United States
Title : A phase 3, multinational, randomized, placebo-controlled, double-blind, crossover trial (IB1001-304) evaluating levacetylleucine in CACNA1A
Chidinma Ejim, IntraBio, United States
Title : Clinical and molecular phenotype of PTRHD1-associated juvenile parkinsonism
Bhavan A Modi, Barrow Neurological Institute at Phoenix Children's, United States